{"organizations": [], "uuid": "924e4cdc73d35698a8c1fc79f21d133a7a745ee1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/10", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/03/01/pr-newswire-pdl-biopharma-to-announce-fourth-quarter-year-end-2017-financial-results-on-march-8-2018.html", "country": "US", "domain_rank": 767, "title": "PDL BioPharma to Announce Fourth Quarter / Year-End 2017 Financial Results on March 8, 2018", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-01T15:00:00.000+02:00", "replies_count": 0, "uuid": "924e4cdc73d35698a8c1fc79f21d133a7a745ee1"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/03/01/pr-newswire-pdl-biopharma-to-announce-fourth-quarter-year-end-2017-financial-results-on-march-8-2018.html", "ord_in_thread": 0, "title": "PDL BioPharma to Announce Fourth Quarter / Year-End 2017 Financial Results on March 8, 2018", "locations": [], "entities": {"persons": [], "locations": [{"name": "nev.", "sentiment": "none"}, {"name": "canada", "sentiment": "none"}, {"name": "united states", "sentiment": "none"}], "organizations": [{"name": "pdl biopharma", "sentiment": "negative"}, {"name": "nasda", "sentiment": "negative"}, {"name": "pdl", "sentiment": "negative"}, {"name": "pdl biopharma, inc.", "sentiment": "neutral"}]}, "highlightText": "", "language": "english", "persons": [], "text": "INCLINE VILLAGE, Nev., March 1, 2018 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will release its fourth quarter, year-end 2017 financial results for the period ended December 31, 2017, on Thursday March 8, 2018, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results. A slide presentation relating to the call will be available via the webcast link on the PDL website.\nConference Call Details\nTo access the live conference call via phone, please dial (800) 668-4132 from the United States and Canada or (224) 357-2196 internationally. The conference ID is 9384627. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available for one week following the call and may be accessed by dialing (855) 859-2056 from the United States and Canada or (404) 537-3406 internationally. The replay passcode is 9384627.\nTo access the live and subsequently archived webcast of the conference call, go to the Company's website at http://www.pdl.com and go to \"Events & Presentations.\" Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.\nAbout PDL BioPharma, Inc.\nPDL seeks to provide a significant return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries. In 2012, PDL began providing alternative sources of capital through royalty monetizations and debt facilities, and in 2016, began acquiring commercial-stage products and launching specialized companies dedicated to the commercialization of these products. To date, PDL has consummated 17 such transactions, of which nine are active and outstanding. PDL has one debt transaction outstanding, representing deployed and committed capital of $20.0 million: CareView; one hybrid royalty/debt transaction outstanding, representing deployed and committed capital of $44.0 million: Wellstat Diagnostics; and five royalty transactions outstanding, representing deployed and committed capital of $396.1 million and $397.1 million, respectively: KYBELLA Â® , AcelRx, University of Michigan, Viscogliosi Brothers and Depomed. PDL's equity and loan investments in Noden represent deployed and committed capital of $179.0 million and $202.0 million, respectively, and its converted equity and loan investment in LENSAR represents deployed capital of $40 million.\nNOTE: PDL, PDL BioPharma, the PDL logo and the PDL BioPharma logo are trademarks or registered trademarks of, and are proprietary, to PDL BioPharma, Inc. which reserves all rights therein.\nView original content with multimedia: http://www.prnewswire.com/news-releases/pdl-biopharma-to-announce-fourth-quarter--year-end-2017-financial-results-on-march-8-2018-300606111.html\nSOURCE PDL BioPharma, Inc.", "external_links": ["http://www.prnewswire.com/news-releases/pdl-biopharma-to-announce-fourth-quarter--year-end-2017-financial-results-on-march-8-2018-300606111.html"], "published": "2018-03-01T15:00:00.000+02:00", "crawled": "2018-03-01T17:17:40.006+02:00", "highlightTitle": ""}